Halting the Epidemic of Addiction and Loss Act of 2025

This bill requires that, when the Department of Health and Human Services (HHS) issues new regulations or guidance on grant programs addressing opioid use disorders, references to an opioid overdose reversal drug (e.g., naloxone) must broadly include any opioid overdose reversal drug approved by the Food and Drug Administration.

Learn about this bill’s status and read its full summary in the Pocket Congress app.